S 1509 · 115th Congress 2017โ€“2019, ended

Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017

Latest action · Jun 29, 2017 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedJun 29, 2017
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to extend by six months the exclusivity period for an approved drug or biological product when the product is additionally approved to prevent, diagnose, or treat a new indication that is a rare disease or condition (also known as an orphan disease). The FDA may revoke an extension if the application for the new indication contained an untrue material statement. The FDA must notify the public of products that receive this extension and patents related to those products. Products may receive only one of these extensions. This extension is in addition to other extensions. Only products approved after enactment of this bill for a new indication that is a rare disease or condition are eligible for an extension.

For a medication to be approved as an orphan drug with seven years of marketing exclusivity when it is the same medication for the same condition as an already approved orphan drug, the sponsor of the new medication must demonstrate that the new medication is clinically superior to the approved medication.

The bill expands to cover brand name drugs provisions that allow generic drugs to be approved and marketed without labeling for pediatric indications when the pediatric indications are protected by patent or marketing exclusivity.

Cosponsors 5

Members who signed on, in the order they did. Signatures ran from Jun 29, 2017 to Jul 31, 2018; 1 is an original cosponsor, there from the day it was introduced.

SeatCosponsorSigned on
D-NJRobert MenendezOriginalJun 29, 2017
D-FLBill NelsonAug 2, 2017
R-SCTim ScottAug 2, 2017
R-FLMarco RubioJan 30, 2018
D-INJoe DonnellyJul 31, 2018

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateHealth, Education, Labor, and Pensions Committee
Referred Jun 29, 2017

Actions 2

Everything that happened, newest first.

  1. Jun 29, 2017Introduced in Senate
  2. Jun 29, 2017Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Printed hearings 1

Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.

NumberHearingCommitteeHeld
S. Hrg. 115-851RARE DISEASES: EXPEDITING TREATMENTS FOR PATIENTS44 pagesHealth, Education, Labor, and Pensions CommitteeOct 3, 2018

CRS reports 1

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 1

Products on other subjects that cite it, usually among other measures.

ProductTitleKindPublished
R44951Regulatory Exclusivity Reform in the 115th Congress ArchivedReportSep 15, 2017

Related bills 1

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
HR 1223OPEN ActRelated billMar 3, 2017

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to amend the Federal Food, Drug, and Cosmetic Act to authorize an extension of exclusivity periods for certain drugs that are approved for a new indication for a rare disease or condition, and for other purposes.
Short Titles as Introduced
Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Jun 29, 2017Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.